Esperion Therapeutics Inc (ESPR) stock news · rev $403.1M
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This ESPR news page leads with what Esperion Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for ESPR yet. We will not pad this page with generic market recap.
Latest reported ESPR revenue for 2025-12-31 was $403.1M. Net income was -$22.7M. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. ESPR currently screens at market cap $816.9M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ESPR stock page; for the tape open the quote page.
ESPR stock news FAQ
What are ESPR's latest revenue and net income?
Latest cached Esperion Therapeutics Inc (ESPR) revenue for Dec 31, 2025 was $403.1M. Net income was -$22.7M. Statements: https://lician.com/financials/espr
How did ESPR revenue change from the prior cached period?
Cached Esperion Therapeutics Inc (ESPR) revenue was up 21.3% from $332.3M (Dec 31, 2024) to $403.1M (Dec 31, 2025). Statements: https://lician.com/financials/espr
What is ESPR's market cap?
Esperion Therapeutics Inc (ESPR) market cap is $816.9M on the latest cached fundamentals snapshot.
What kind of company is ESPR?
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Where is ESPR stock news listed?
Cached stock news for Esperion Therapeutics Inc (ESPR) is listed at https://lician.com/news/espr. Filings: https://lician.com/sec/espr
Not investment advice.